Heart failure & cardiomyopathies
Cost-effectiveness of intravenous ferric derisomaltose for patients with heart failure and iron deficiency in the UK based on the IRONMAN trial results
Main finding · Quality-adjusted life years (QALYs)Result — go to the resultDifference 0.016 QALYs 95% CrI 0.002–0.032Authors' conclusion
Over a one-year time horizon, a within-trial analysis showed that administering FDI to patients with heart failure and iron deficiency was cost saving compared to usual care, driven primarily by reduced rates of hospitalisation.
Study context
- Population
- Patients with new or established heart failure, iron deficiency, and a left ventricular ejection fraction ≤45%
- Comparison
- Ferric derisomaltose (FDI) compared to usual care
- Outcome
- Quality-adjusted life years (QALYs)
- Follow-up
- One year
Methodological detailsbased on individual patient-level data from the IRONMAN trial, one-year time horizon, perspective of NHS England, within-trial analysis
- Based on individual patient-level data from the IRONMAN trial
- One-year time horizon
- Perspective of NHS England
- Within-trial analysis
Main finding
As reported in the abstract
Difference
0.016 QALYs
95% CrI 0.002–0.032
By group
FDIvs usual care
difference 0.016 QALYs (95% CrI 0.002–0.032)
Further findings
| Outcome | Savings (per patient) (95% CrI) |
|---|---|
| Costs per patient · over one yearSavings with FDI; 15% less than the cost of usual care | £580 (£493-£678) |
- Costs per patient — Incremental costs of acquiring and administering FDI
- £357
- Costs per patient — Savings due to avoided hospitalisations and end-of-life care
- £936
Original publication
Cost-effectiveness of intravenous ferric derisomaltose for patients with heart failure and iron deficiency in the UK based on the IRONMAN trial results. ESC Heart Fail. Published 14 October 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →